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W e considered the association between diabetes and risk
of endometrial cancer using data from a large case-control
study conducted in Italy. Cases were 752 women with inci-
dent, histologically confirmed endometrial cancer F75 years
of age (median age 60 years, range 28–74) admitted to a
network of hospitals in Milan. Controls were 2,606 patients
(median age 54 years, range 25–74) agedF75 years, admitted
for acute non-neoplastic, non-gynecological, non-hormone-
related conditions to the same network of hospitals where
caseshad been identified. A total of 132 (17.6%) casesand 116
controls(4.5%) reported a historyof diabetes. The correspond-
ing multivariate odds ratio (OR) was 2.9 [95% confidence
interval (CI) 2.2–3.9] . No association emerged with diabetes
diagnosed under age 40 (likely to be insulin-dependent diabe-
tes), whereas the OR of endometrial cancer was 3.1 (95%CI
2.3–4.2) for diabetes diagnosed at age H40 years. The OR of
endometrial cancer in women with history of diabeteswas3.0
for women with a body massindex (BMI) (QI) kg/m2F25, 3.6
for those with a BMI of 25–29, and 3.3 for those with a BMI
H30. No consistent interaction or modifying effect was
observed for any other covariate. Our results confirm that
non-insulin-dependent diabetes is associated with the risk of
endometrial cancer. The association maybe mediated through
elevated oestrogen levels in diabetic women, hyperinsulin-
emia or insulin-like growth factor-I (IGF-I). Int. J. Cancer
81:539–542, 1999.
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Several studies have reported an increased risk of cancer of
uterine corpus in women with a history of diabetes (Brinton et al.,
1992; La Vecchia et al., 1994; Levi et al., 1993; Maatela et al.,
1994; O’Mara et al., 1985; Parazzini et al., 1991; Rubin et al., 1990;
Weiderpass et al., 1997; Wideroff et al., 1997). The biological
explanation of this association, however, remains unclear. The
observations that diabetes is more common in overweight women
(a well-defined risk factor for endometrial cancer; Parazzini et al.,
1991) and that endometrial cancer is a disease of affluent societies,
have suggested that a history of diabetes may represent an indicator
of nutritional factors related to endometrial cancer risk. Few
studies, however, have taken into account the potential confound-
ing role of obesity and other potential confounding factors (O’Mara
et al., 1985).
Attention has been paid to the role of hyperinsulinemia, a feature
of non-insulin dependent diabetes mellitus (NIDDM), on hormone-
related neoplasias (Kazer, 1995). Hyperinsulinemia appears to
increase ovarian steroid production (Poretsky and Kalin, 1987),
stimulate conversion of testosterone to oestradiol (Garzo and
Dorrington, 1984) and suppress circulating concentrations of
sex-hormone-binding-globulin (SHBG) (Nestler et al., 1991).
Further, hyperinsulinemia is associated with high levels of insulin-
like growth factor-I (IGF-I; Kazer, 1995), which may act synergis-
tically with an increased oestrogen activity, and IGF-I has been
suggested to have a carcinogenic effect on breast and colon cancer
(Aaronson, 1991; Giovannucci, 1995; Kazer, 1995; La Vecchia
et al., 1997).
We have therefore considered the association between diabetes
and risk of endometrial cancer using data from a case-control study
conducted in Italy (Parazzini et al., 1998), based on a large sample
size, and with the availability of detailed information on covariates
of interest.
SUBJECTS AND METHODS
Between 1983 and 1995, we conducted a case-control study on
risk factors for endometrial cancer. The design of this study has
been described previously (Parazzini et al., 1998). Cases were 752
women with histologically confirmed endometrial cancer who were
,75 years (median age 60 years, range 28–74) whose diagnosis
dated back #1 year. They were admitted to the Ospedale Maggiore
(including the 4 largest teaching and general hospitals in the
Greater Milan area), the University Obstetric and Gynecology
Clinics, and the National Cancer Institute of Milan. All cases were
interviewed in hospital.
Controls were patients ,75 years of age admitted for acute,
non-gynecological non-hormone-related, non-neoplastic condi-
tions to the same network of hospitals where cases had been
identified. Women who had undergone hysterectomy were not
eligible as controls. A total of 2,606 controls (median age 54 years,
range 25–74) were included in the present analysis. Of these, 34%
were admitted for traumatic conditions (mostly fractures and
sprains), 30% for non-traumatic orthopaedic disorders (mostly low
back pain and disk disorders), 15% for surgical conditions (mostly
abdominal, such as acute appendicitis or strangulated hernia) and
21% for other miscellaneous illnesses, such as eye, ear, nose and
throat, or dental disorders. Fewer than 4% of cases and controls
approached for interview refused to participate.
Trained interviewers used a standard questionnaire to identify
and question cases and controls. Information was collected on
general characteristics and habits, gynecological and obstetric data,
and history of use of oral contraceptives and female hormones for
other indications. Height and weight were self-reported by women.
The questionnaire also ascertained information on diabetes and
other selected diseases or medical procedures. By definition, these
had to precede by at least 1 year the onset of the disease that led to
admission. Age at onset/first diagnosis was recorded. Information
regarding diabetes and other diseases was checked with medical
records whenever useful by the interviewer, thus minimizing the
risk of diagnostic errors.
Women were defined as pre-menopausal (with regular menstrua-
tion), in peri-menopause (women whose menstrual bleedings had
naturally ceased for less than 12 months) or post-menopausal
(menses had naturally ceased for 12 or more months). Age at
menopause was considered the age at last menstruation. Ovariecto-
mized women were included in the post-menopausal group consid-
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ering the date of surgery as the date of menopause. Women using
hormonal replacement therapy were considered post-menopausal if
reported a period lasting 12 or more months without spontaneous
menstrual cycles.
Data analysis
We estimated the odds ratios (OR) of endometrial cancer,
together with their 95% confidence intervals (CI), according to
history of diabetes. Unconditional multiple logistic regression, with
maximum-likelihood fitting, was used (Breslow and Day, 1980).
Included in the regression equations were terms for age (as
continuous variable), calendar year at interview, education, body
mass index (BMI) (as categorized variable, ,25, 25–30, .30),
parity, oral contraceptive and hormonal replacement therapy use,
age at menopause, hypertension and smoking.
RESULTS
Table I presents the distribution of cases and controls according
to age, education and selected risk factors for endometrial cancer.
Cases were less educated, less frequently smokers and pre-
menopausal, and more frequently nulliparous and overweight, and
more frequently reported a history of hypertension and estrogen
replacement therapy use. These factors, therefore, were adjusted
for in subsequent analyses.
Table II presents the distribution of cases and controls according
to history of diabetes. A total of 132 (17.6%) cases and 116 controls
(4.5%) reported a history of diabetes. The corresponding multivari-
ate OR was 2.9 (95% CI 2.2–3.9). No association emerged with
diabetes diagnosed under age 40 (which is likely to be insulin-
dependent diabetes), whereas the OR of endometrial cancer was 3.1
(95% CI 2.3–4.2) for the disease diagnosed at age $40 years.
Considering only women with a diagnosis of diabetes at 40 years of
age or older, the OR of endometrial cancer was 3.8 for women
reporting a diagnosis of diabetes less than 5 years before diagnosis
of endometrial cancer and 3.3 for those reporting diagnosis of
diabetes $5 years before.
Table III illustrates the relationship between diabetes mellitus
and the risk of endometrial cancer in strata of age and other selected
covariates. No significant interaction was observed, and in all the
strata considered the OR of endometrial cancer for a history of
diabetes was over 2. In particular, the OR was 2.6 at age 40–59
years and 3.4 at age 60–74 years; OR was 3.0 for women with BMI
,25 kg/m2, 3.6 for those with BMI 25–29 and 2.9 for those with a
BMI $30. Likewise, the ORs were similar across strata of age at
menopause, smoking and hypertension.
DISCUSSION
Potential limitations of the study must be considered. First of all,
information bias should be taken into account, because endometrial
cancer cases can be more sensitized than controls in reporting
history of diabetes. However, it is difficult that a major long-term
condition like diabetes is appreciably and systematically misre-
ported.
Further, the hospital-based design represents an optimal frame-
work for analysing medical histories (Breslow and Day, 1980;
Kelly et al., 1990). Cases and controls, in fact, were similarly
investigated and should be similarly sensitized towards recalling
TABLE I – DISTRIBUTION OF 752 CASES OF ENDOMETRIAL CANCER AND 2,606
CONTROLS ACCORDING TO AGE AND SELECTED COVARIATES
(MILAN, ITALY, 1983–1995)
Endometrial cancer Controls
Number (%) Number (%)
Age (years)
,45 38 (5.1) 640 (24.6)
45–54 147 (19.3) 692 (26.6)
55–64 307 (40.8) 735 (28.2)
$65 260 (34.6) 539 (20.7)
Education (years)
,7 523 (69.5) 1536 (58.9)
7–11 147 (19.5) 634 (24.3)
$12 82 (10.9) 436 (16.7)
Body mass index (kg/m2)
,25 298 (39.6) 1580 (60.6)
25–30 255 (33.9) 776 (29.8)
.30 199 (26.5) 250 (9.6)
Oral contraceptive (years
of use)
Never 726 (96.5) 2366 (90.8)
#2 12 (1.6) 119 (4.6)
.2 14 (1.9) 121 (4.6)
Hormone replacement therapy
(years of use)
Never used 663 (88.2) 2512 (96.4)
#2 65 (8.6) 79 (3.0)
.2 24 (3.2) 15 (0.6)
Age at menopause (years)
Premenopause 141 (18.8) 1208 (39.4)
,50 219 (29.1) 712 (27.3)
$50 392 (52.1) 866 (33.2)
Parity
0 162 (21.7) 512 (19.7)
1 175 (23.5) 624 (24.0)
2 209 (28.0) 804 (30.9)
$3 200 (26.8) 662 (25.4)
Hypertension
No 506 (67.3) 2154 (82.7)
Yes 246 (32.7) 452 (17.3)
Smoking
Never 608 (80.9) 1783 (68.4)
Ever 144 (19.1) 823 (31.6)
In some cases the sum of strata does not add up to total because of
missing values.
TABLE II – DISTRIBUTION OF 752 CASES OF ENDOMETRIAL CANCER AND 2,606 CONTROLS ACCORDING TO HISTORY
OF DIABETES, AND CORRESPONDING ODDS RATIOS (OR)1 (MILAN, ITALY, 1983–1995)
Cases Controls OR (95% CI)
Number (%) Number (%) MH2 MLV3
History of diabetes
Never 620 (82.4) 2490 (95.5) 14 14
Ever 132 (17.6) 116 (4.5) 3.6 (2.7–4.8) 2.9 (2.2–3.9)
at age ,40 4 (0.5) 15 (0.6) 1.0 (0.3–3.4) 1.0 (0.3–3.6)
at age $40 128 (17.0) 101 (3.9) 3.8 (2.9–5.1) 3.1 (2.3–4.2)
Years since diagnosis of diabetes1
,5 64 (8.7) 42 (1.9) 5.1 (3.3–7.6) 3.8 (2.5–5.9)
$5 64 (8.7) 59 (2.7) 3.0 (2.1–4.5) 2.6 (1.8–3.9)
CI 5 confidence interval.–1Subjects aged 40 years or more only.–2Mantel Haenszel (MH) estimates
adjusted for age.–3Derived from multiple logistic regression equations including term for age, calendar
year at interview, education, Quetelet’s index, parity, oral contraceptive and hormone replacement therapy
use, age at menopause, hypertension, and smoking.–4Reference category.
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diseases in the past. A multicentre, case-control study from the
United States, Canada and Israel found a correlation coefficient
more than 0.9 for history of diabetes in repeated interviews (Kelly
et al., 1990). Furthermore, the 4.5% disease prevalence in the
comparison group is consistent with estimates from Italian national
population-based surveys (Negri et al., 1988). Cases and controls
were identified in hospitals with comparable catchment area, and
participation was almost complete.
With regard to confounding, the results were consistent in strata
of selected covariates, the ORs did not change markedly after
taking into account several covariates, including the main recognised
risk factors for endometrial cancer, and in particular obesity, which,
in principle, could be a relevant confounding factor. Indeed, the
multivariate OR of endometrial cancer for diabetic women com-
puted without allowance for BMI was 3.3 (95% CI 2.5–4.5). It has
been suggested, moreover, that the association between obesity and
endometrial cancer is unlikely to be mediated through elevated
insulin levels (Troisi et al., 1997), pointing to an independent
mechanisms of the 2 risk factors. The possibility of a residual
confounding factor (due to an incomplete adjustment for over-
weight and/or dietary habits) cannot, however, be excluded. Recent
loss of weight due to the tumor may represent a potential bias. We
had not collected information on stage of the disease, as a proxy for
duration of the condition; however, in the participating centre about
90% of endometrial cancer cases are diagnosed at stage I (La
Vecchia et al., 1983).
Our results indicate that the association between endometrial
cancer risk and diabetes mellitus is limited to NIDDM. Indeed,
even in the absence of direct information on type of diabetes, only
diabetes mellitus diagnosed after 40 years of age was associated
with the risk of endometrial cancer. This finding suggests that
hyperinsulinemia and hence, possibly, IGF-I is a correlate of
endometrial cancer risk. However, Troisi et al. (1997) did not found
any association between C-peptide, a proxy for insulin production,
and endometrial cancer.
The present results are consistent with most previous epidemio-
logical findings. The OR for a history of diabetes mellitus was
between 2 and 3 in most case-control studies of endometrial cancer
(Parazzini et al., 1991) and the standardized incidence ratio of
endometrial cancer was 1.7 (95% CI 1.5–1.9) in a Swedish cohort
study of 80,000 diabetic women, after exclusion from the analysis
of women with a diagnosis of obesity (Weiderpass et al., 1997).
The latter findings are unlikely to be affected by information or
recall bias.
In conclusion, our results confirm, providing more accurate
quantification than previously available, that NIDDM is associated
with the risk of endometrial cancer, that this association persists
after taking into account the potential confounding effect of
recognised risk factors for endometrial cancer, particularly over-
weight, and is consistent across strata of major identified covari-
ates. This association may be related to elevated estrogen levels in
diabetic women (Deutsch and Benjamin, 1978), hyperinsulinemia
or IGF-I, which is a promotor of carcinogenesis in vitro (Preston-
Martin et al., 1990), as also suggested to explain the association
between diabetes and colon and breast cancer.
ACKNOWLEDGEMENTS
This work was conducted with the contribution of the Italian
Association for Research on Cancer, Milan. The authors thank Mrs.
I. Garimoldi for editorial assistance, Dr. M. Parazzini and Dr. C.
Mezzanotte for their help in data management.
REFERENCES
AARONSON, S.A., Growth factors and cancer. Science, 254, 1146–1153
(1991).
BRESLOW, N.E. and DAY, N.E., Statistical methods in cancer research. I. The
analysis of case-control study. IARC Scientific Publ. 32. IARC, Lyon,
France (1980).
BRINTON, L.A., BERMAN, M.L. and MORTEL, R., Reproductive, menstrual,
and medical risk factors for endometrial cancer: results from a case-control
study. Amer. J. Obstet. Gynecol., 167, 1317–1325 (1992).
DEUTSCH, S. and BENJAMIN, F., Effect of diabetic status on fractionated
estrogen levels in postmenopausal women. Amer. J. Obstet. Gynecol., 130,
105–106 (1978).
GARZO, V.G. and DORRINGTON, J.H., Aromatase activity in human granulosa
cells during follicular development and the modulation by follicle-
stimulating hormone and insulin. Amer. J. Obstet. Gynecol., 148, 657–662
(1984).
GIOVANNUCCI, E., Insulin and colon cancer. Cancer Causes Control, 6,
164–179 (1995).
KAZER, R.R., Insulin resistance, insulin-like growth factor I and breast
cancer: a hypothesis. Int. J. Cancer, 62, 403–406 (1995).
KELLY, J.P., ROSENBERG, L., KAUFMAN, D.W. and SHAPIRO, S., Reliability of
personal interview data in a hospital-based case-control study. Amer. J.
Epidemiol., 131, 79–90 (1990).
LA VECCHIA, C., FRANCESCHI, S., PARAZZINI, F., COLOMBO, E., COLOMBO, F.,
LIBERATI, A. and MANGIONI, C., Ten-year survival in 290 patients with
endometrial cancer: prognostic factors and therapeutic approach. Brit. J.
Obstet. Gynaecol., 90, 654–661 (1983).
LA VECCHIA, C., NEGRI, E., DECARLI, A. and FRANCESCHI, S., Diabetes
mellitus and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev., 6,
1007–1010 (1997).
LA VECCHIA, C., NEGRI, E., FRANCESCHI, S., D’AVANZO, B. and BOYLE, P., A
TABLE III – ODDS RATIO (OR)1 OF ENDOMETRIAL CANCER ACCORDING TO
HISTORY OF DIABETES DIAGNOSED AT AGE $40 IN STRATA




OR (95% CI) x2 interaction
Age (years)
40–59 32:36 2.6 (1.5–4.5)
$60 99:65 3.4 (2.3–5.0) 1.26 (1 df)
( p 5 NS)
Education (years)
,7 100:84 2.8 (2.0–3.9)
$7 28:17 5.7 (2.8–11.5) 2.37 (1 df)
( p 5 NS)
Body mass index (kg/m2)
,25 29:41 3.0 (1.8–5.2)
25–29 44:35 3.6 (2.1–6.0) 0.60 (2 df)
$30 55:25 3.3 (1.9–5.8) ( p 5 NS)
Hormone replacement
therapy
Never users 117:96 3.3 (2.4–4.5)
Ever users 11:5 2.1 (0.6–7.1) 0.07 (1 df)
( p 5 NS)
Age at menopause (years)
Premenopause 9:8 5.5 (1.8–16.8)
,50 47:46 3.0 (1.8–4.9)
$50 72:47 3.1 (2.0–4.7) 0.47 (2 df)
( p 5 NS)
Smoking habits
Never smokers 104:85 2.8 (2.0–3.9)
Ever smokers 24:16 4.8 (1.8–12.6) 1.71 (1 df)
( p 5 NS)
Hypertension
No 63:62 3.2 (2.2–4.8)
Yes 65:39 3.0 (1.9–4.8) 0.01 (1 df)
( p 5 NS)
CI 5 confidence interval; df 5 degrees of freedom; NS 5 not
significant.–1Derived for multiple logistic regression equation includ-
ing terms for age, calendar year at interview, education, Quetelet’s
index, parity oral contraceptive and hormone replacement therapy use,
age at menopause, hypertension, and smoking.–2Reference category:
no diabetes.
541DIABETES AND ENDOMETRIAL CANCER
case-control study of diabetes mellitus and cancer risk. Brit. J. Cancer, 70,
950–953 (1994).
LEVI, F., LA VECCHIA, C., GULIE, C., FRANCESCHI, S. and NEGRI, E.,
Oestrogen replacement treatment and the risk of endometrial cancer: an
assessment of the role of covariates. Europ. J. Cancer, 29, 1445–1449
(1993).
MAATELA, J., AROMAA, A., SALMI, T., POHJA, M., VUENTO, M. and
GRO¨NROOS, M., The risk of endometrial cancer in diabetic and hypertensive
patients: a nationwide record-linkage study in Finland. Ann. Chir. Gynae-
col., 83, 20–24 (1994).
NEGRI, E., PAGANO, R., DECARLI, A. and LA VECCHIA, C., Body weight and
the prevalence of chronic diseases. J. Epidemiol. Community Health, 42,
24–29 (1988).
NESTLER, J.E., POWERS, L.P., MATT, D.W., STEINGOLD, K.A., PLYMATE, S.R.,
RITTMASTER, R.S., CLORE, J.N. and BLACKARD, W.G., A direct effect of
hyperinsulinemia on serum sex hormone-binding globulin levels in obese
women with the polycystic ovary syndrome. J. clin. Endocrinol. Metab.,
72, 83–89 (1991).
O’MARA, B.A., BYERS, T. and SHOENFELD, E., Diabetes mellitus and cancer
risk: a multisite case-control study. J. chron. Dis., 38, 435–441 (1985).
PARAZZINI, F., LA VECCHIA, C., BOCCIOLONE, L. and FRANCESCHI, S., The
epidemiology of endometrial cancer. Gynecol. Oncol., 41, 1–16 (1991).
PARAZZINI, F., NEGRI, E., LA VECCHIA, C., BENZI, G., CHIAFFARINO, F.,
POLATTI, A. and FRANCESCHI, S., Role of reproductive factors on the risk of
endometrial cancer. Int. J. Cancer, 76, 784–786 (1998).
PORETSKY, L. and KALIN, M.F., The gonadotropic function of insulin.
Endocrinol. Rev., 8, 132–141 (1987).
PRESTON-MARTIN, S., PIKE, M.C., ROSS, R.K., JONES, P.A. and HENDERSON,
B.E., Increased cell division as a cause of human cancer. Cancer Res., 50,
7415–7421 (1990).
RUBIN, G.L., PETERSON, H.B., LEE, N.C., MAES, E.F., WINGO, P.A. and
BECKER, S., Estrogen replacement therapy and the risk of endometrial
cancer: remaining controversies. Amer. J. Obstet. Gynecol., 162, 148–154
(1990).
TROISI, R., POTISCHMAN, N., HOOVER, R.N., SIITERI, P. and BRINTON, L.A.,
Insulin and endometrial cancer. Amer. J. Epidemiol., 146, 476–482 (1997).
WEIDERPASS, E., GRIDLEY, G., NYREN, O., EKBOM, A., PERSSON, I. and
ADAMI, H.O., Diabetes mellitus and risk of large bowel cancer [letter]. J.
nat. Cancer Inst., 89, 1232–1233 (1997).
WIDEROFF, L., GRIDLEY, G., MELLEMKJAER, L., CHOW, W.H., LINET, M.,
KEEHN, S., BORCH-JOHNSON, K. and OLSEN, J.H., Cancer incidence in a
population-based cohort of patients hospitalized with diabetes mellitus in
Denmark. J. nat. Cancer Inst., 89, 1360–1365 (1997).
542 PARAZZINI ET AL.
